Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- ALEC
- Price
- 1.97
- Stock movement down
- -0.03 (-1.35%)
- Company name
- Alector Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 240.13M
- Ent value
- 436.92M
- Price/Sales
- 11.41
- Price/Book
- 7.83
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -10.72%
- 1 year return (CAGR)
- 45.70%
- 3 year return (CAGR)
- -32.68%
- 5 year return (CAGR)
- -33.60%
- 10 year return (CAGR)
- -
Last updated: 2026-03-13
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ALEC does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 11.41 |
| Price to Book | 7.83 |
| EV to Sales | 20.76 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 109.15M |
| EPS (TTM) | -1.39 |
| FCF per share (TTM) | -1.79 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 21.05M |
| Gross profit (TTM) | 18.79M |
| Operating income (TTM) | -148.01M |
| Net income (TTM) | -142.93M |
| EPS (TTM) | -1.39 |
| EPS (1y forward) | -0.99 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 89.27% |
| Operating margin (TTM) | -703.29% |
| Profit margin (TTM) | -679.16% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 65.80M |
| Net receivables | 0.00 |
| Total current assets | 266.45M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 293.24M |
| Accounts payable | 1.69M |
| Short/Current long term debt | 36.23M |
| Total current liabilities | 69.50M |
| Total liabilities | 262.59M |
| Shareholder's equity | 30.65M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -184.03M |
| Capital expenditures (TTM) | 41.00K |
| Free cash flow (TTM) | -184.07M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -466.34% |
| Return on Assets | -48.74% |
| Return on Invested Capital | -356.69% |
| Cash Return on Invested Capital | -459.36% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.24 |
| Daily high | 2.33 |
| Daily low | 2.13 |
| Daily Volume | 649K |
| All-time high | 39.49 |
| 1y analyst estimate | 2.10 |
| Beta | 0.55 |
| EPS (TTM) | -1.39 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 3 Mar 2026 |
Downside potential
Loading...
Downside potential data
| ALEC | S&P500 | |
| Current price drop from All-time high | -95.01% | -1.82% |
| Highest price drop | -97.71% | -56.47% |
| Date of highest drop | 10 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -64.97% | -10.84% |
| Avg time to new high | 78 days | 12 days |
| Max time to new high | 1177 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
240.13M
Marketcap category
Small-cap
Description
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
Employees
103
Website
Investor relations
-
SEC filings
CEO
Arnon Rosenthal
Country
USA
City
South San Francisco
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page